Charles Moore, MD
Cardiovascular Disease · Birmingham, ALNPI 1699795641
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,850 of the $47,270 with a category attached, or 78.0%. Pfizer accounts for 85.6% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $16,861 and has fallen 99.9% since, to $22 in 2025. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $119.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$40K
- Abiomed$2K
- Novartis$516
- Johnson & Johnson$473
- Boehringer Ingelheim$400
- Actelion Pharmaceuticals US, Inc.$381
- plus $3K from 29 others
Across 19 payments — averaging $6541.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$117K
- Sanofi US Services Inc.$7K
What the payments were for
- Speaking & faculty fees$36,85078%
- Travel & lodging$2,0024%
- Food & beverage$8,28018%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 99 | $40,469 |
| Abiomed | 42 | $1,628 |
| Novartis | 37 | $516 |
| Johnson & Johnson | 29 | $473 |
| Boehringer Ingelheim | 22 | $400 |
| Actelion Pharmaceuticals US, Inc. | 16 | $381 |
| E.r. Squibb & Sons, L.L.C. | 21 | $367 |
| Cvrx, Inc. | 2 | $264 |
| Merck | 15 | $261 |
| Bayer | 16 | $256 |
| Livanova USA, Inc. | 2 | $239 |
| Amgen | 16 | $229 |
| United Therapeutics Corporation | 11 | $193 |
| AstraZeneca | 12 | $162 |
| Vifor Pharma, Inc. | 3 | $153 |
| Boston Scientific | 3 | $143 |
| Medtronic | 2 | $138 |
| Daxor Corporation | 2 | $130 |
| Abbott | 6 | $129 |
| Astellas Pharma US Inc | 6 | $124 |
| Irhythm Technologies, Inc. | 6 | $113 |
| Gilead | 7 | $108 |
| Impulse Dynamics (USA) Inc. | 5 | $100 |
| Nuwellis, Inc. | 1 | $49 |
| Akcea Therapeutics, Inc. | 3 | $44 |
| Dendreon Pharmaceuticals LLC | 1 | $31 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Lantheus Medical Imaging, Inc. | 2 | $23 |
| Integra Lifesciences Corporation | 1 | $22 |
| Blue Earth Diagnostics | 1 | $21 |
| Biotronik Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $16 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$35,682
- Impella$274
- Barostim Neo System$264
- LifeSPARC$239
- Veltassa$125
- HeartWare HVAD$119
- ELIQUIS$106
How this compares
$47,270 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 39 | $846,162 |
| EntrestoSacubitril/Valsartan | 219 | $176,139 |
| LetairisAmbrisentan | 13 | $165,694 |
| FarxigaDapagliflozin Propanediol | 90 | $66,937 |
| JardianceEmpagliflozin | 77 | $58,419 |
| EliquisApixaban | 49 | $39,370 |
| VerquvoVericiguat | 29 | $20,824 |
| Tacrolimus | 57 | $15,490 |
| TrulicityDulaglutide | 11 | $10,879 |
| Tadalafil | 16 | $4,968 |
| Spironolactone | 231 | $2,358 |
| Mycophenolate Mofetil | 15 | $1,390 |
| Bumetanide | 25 | $1,376 |
| Eplerenone | 17 | $1,241 |
| Digoxin | 68 | $1,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $40,469 | $885,53388 claims |
| NovartisEntresto | $516 | $176,139219 claims |
| GileadLetairis | $108 | $165,69413 claims |
| AstraZenecaFarxiga | $162 | $66,93790 claims |
| Boehringer IngelheimJardiance | $400 | $58,41977 claims |
| MerckVerquvo | $261 | $20,82429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Birmingham
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Farrell MendelsohnBirmingham$51K
- Christopher DegroatBirmingham$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.